Pure Global
NCT06317285

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GlaxoSmithKline·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention
GSK3915393
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
GlaxoSmithKline
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Mar 19, 2026
Enrollment
150 participants
Primary outcome

Absolute Change from Baseline in Forced Vital Capacity (FVC) in milliliters (mL) at Week 26

Summary

Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs
 and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in
 participants with IPF for the first time. The study will assess the safety and effectiveness
 of GSK3915393 in IPF participants.

ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06317285
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06317285 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.